Drug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Drug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors"

Transcription

1 Drug Class Review Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors Final Original Report July 2015 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. Reports are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Kim Peterson, MS Brittany Holzhammer, MPH Marian McDonagh, PharmD Marian McDonagh, PharmD, Principal Investigator Pacific Northwest Evidence-based Practice Center Roger Chou, MD, Director Marian McDonagh, PharmD, Associate Director Copyright 2015 by Oregon Health & Science University Portland, Oregon All rights reserved.

2 INTRODUCTION HMG-CoA reductase inhibitors, or statins, have been the primary therapeutic intervention for hypercholesterolemia for decades. They have been successful in reducing the risk of major cardiovascular (CV) events and mortality in a wide range of at-risk individuals. However, statins (alone or in combination with other lipid-lowering therapies, such as ) are not always adequate in reducing cholesterol levels in some patients, even at higher doses (e.g., patients with heterozygous hypercholesterolemia). Additionally, some patients cannot tolerate statins. Within the last decade, the relationship between proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesterol metabolism has been increasingly studied. PCSK9 signals the degradation of the low-density lipoprotein receptor, which causes levels plasma low-density lipoprotein cholesterol to increase. Monoclonal antibodies directed at inhibiting PCSK9 are undergoing development as novel therapies in response to the therapeutic gaps posed by current standard therapies to treat hypercholesterolemia. Scope and Key Questions Currently, there are three PCSK9 inhibitors in phase III testing (Table A), which are the focus of this review. These interventions have not yet been approved by the U.S. Food and Drug Administration. The purpose of this review is to compare the benefits and harms of these drugs, with or without other lipid lowering drugs, with emphasis on health outcomes and longer-term harms. Table A. PCSK9 Inhibitors Included in this Report Generic Name Company Code Phase of Development BLA Submitted Estimated FDA Approval Evolocumab AMG 145 Phase II/III 8/28/14 Summer 2015 Alirocumab SAR Phase III 11/27/2014 7/24/2015 (REGN727) Bococizumab RN316 (PF ) Phase III Unclear 2016 Abbreviations: BLA, biologics license application; FDA, U.S. Food & Drug Administration In consultation with participating organizations, the Pacific Northwest Evidence-based Practice Center drafted Key Questions and inclusion criteria reflecting populations, drugs, and outcome measures of interest to clinicians and patients. The following Key Questions were approved to guide this review: 1. What are the comparative benefits and harms of PCSK9 inhibitors in patients with heterozygous and homozygous familial hypercholesterolemia? 2. What are the comparative benefits and harms of PCSK9 inhibitors in patients with hypercholesterolemia who are unable to use statins due to intolerance or any other reasons? 3. What are the comparative benefits and harms of PCSK9 inhibitors in patients with nonfamilial hypercholesterolemia who have not achieved LDL-C <100 mg/dl or <70 mg/dl with their current lipid lowering regimen (e.g., statin, with or without, etc.)? PCSK9 Inhibitors 2 of 9

3 4. Do the comparative benefits and harms of PCSK9 inhibitors differ when used in different patient subgroups based on demographics, socioeconomic status, other medications, or comorbidities? METHODS To identify relevant studies, we searched Ovid MEDLINE (through February Week ), the Cochrane Database of Systematic Reviews (2009 through 2015), the Cochrane Central Register of Controlled Trials (2009 through January 2015), and Scopus (2010 through 2015) using names of included drugs as search terms. We attempted to identify additional studies through hand searches of reference lists of included studies and reviews. In addition, we searched ClinicalTrials.gov for unpublished results and additional publications. Finally, we requested dossiers of published and unpublished information from the relevant pharmaceutical companies for this review. All received dossiers were screened for studies or data not found through other searches. We assessed risk of bias (quality rating) of trials based on predefined criteria developed by the United States Preventive Services Task Force (ratings: good-fair-poor) and the National Health Service Centre for Reviews and Dissemination. We graded strength of evidence based on the guidance established for the Evidence-based Practice Center Program of the Agency for Healthcare Research and Quality. RESULTS Of 205 citations identified from electronic databases, 1 pharmaceutical manufacturer dossier submission, ClinicalTrials.gov, suggestions in public comments on the draft report and hand searches, we included 17 trials. We identified no completed studies with health outcomes as primary outcomes for alirocumab, bococizumab or evolocumab, but we identified ongoing studies with such primary outcomes for evolocumab (FOURIER) and for bococizumab (SPIRE-1 and SPIRE-2) with estimated completion dates in There were no published trials of bococizumab, despite 5 completed trials identified in ClinicalTrials.gov, 4 with completion dates between October 2011 and October There were no completed or ongoing studies that directly compared different PCSK9 inhibitors. The evidence is summarized below first by drug and then by population/key Question, and in the Summary Table (Table B). Part I. Evidence for Evolocumab Heterozygous Familial Hypercholesterolemia Compared to placebo, there was high-strength evidence from 2, 12-week randomized controlled trials (RCTs) (fair- and good-quality, N=499) that evolocumab, dosed at 140 mg every 2 weeks to weeks, achieved a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients who were largely taking a high-intensity statin plus with a greater improvement in high-density lipoprotein cholesterol (HDL-C) and no differences in harms (moderate-strength evidence). PCSK9 Inhibitors 3 of 9

4 Homozygous Familial Hypercholesterolemia Low-strength evidence based on 1 small, good-quality trial (N=50) suggested that evolocumab weeks reduced LDL-C significantly more than placebo at 12 weeks in patients taking a maximum statin dose and. There was no difference in HDL-C change and there was no difference in the percentage of patients with serious adverse events, neurocognitive events, or those withdrawing due to treatment emergent adverse events. However, compared with placebo, patients treated with evolocumab experienced fewer overall treatment emergent adverse events and potential injection-site reactions but more reports of gastroenteritis. Statin Intolerant Patients In statin-intolerant patients, 2 fair-quality 12-week RCTs (GAUSS and GAUSS-2; N=434) provided low-strength evidence that evolocumab led to a greater reduction in LDL-C when dosed at 280 mg every 4 weeks to or 140 mg every 2 weeks, while having generally similar effects on HDL-C and harms. There was also low-strength evidence from the GAUSS study (N=62) that the combination of evolocumab weeks plus 10 mg led to a greater percent LDL-C reduction than 10 mg alone, but insufficient evidence to draw conclusions on other outcomes. Patients Not Achieving LDL-C <100 mg/dl or <70 mg/dl While on Treatment for Hypercholesterolemia Evolocumab Compared with Ezetimibe (Both with Statin Therapy) In a comparison of evolocumab and (both with statin therapy), the LAPLACE-2 study (N=329), provided low-strength evidence that when added to either atorvastatin 10 mg or 80 mg, compared to 10 mg, evolocumab 420 mg monthly resulted in higher rates of meeting an LDL-C target of <70 mg/dl at 12 weeks, with similar rates of patients with overall adverse events. This study provided insufficient evidence to draw conclusions about HDL-C or serious adverse events or withdrawal due to adverse events, due to the small magnitude of change or event rates. Evolocumab Compared with Placebo in Patients with Varying CV Risk In short-term comparisons of evolocumab and placebo, LAPLACE-TIMI 57 AND LAPLACE-2 (N=996 for placebo comparison) provided high-strength evidence that at 12 weeks in patients with varying risk levels and not meeting LDL-C targets, significantly more patients taking evolocumab 420 mg monthly than taking placebo (both with statin therapy) achieved an LDL-C of <70 mg/dl, and had greater percent reduction in LDL-C. There was also moderate-strength evidence of modest HDL-C increases with evolocumab 420 mg monthly, and moderate- to highstrength evidence of no differences in harms outcomes. Based on 1 good quality trial longer-term (N=901; 52 weeks) there was moderatestrength evidence that evolocumab 420 mg given every 4 weeks also resulted in significantly more patients achieving a goal of LDL-C <70 mg/dl compared with placebo, low-strength evidence of a modest increase in HDL-C, and evidence of no difference in harms (moderate- and high-strength depending on outcome). Clinically important and statistically significant differences were seen in all CV risk subgroups. PCSK9 Inhibitors 4 of 9

5 Evolocumab Compared with Placebo in Patients with High CV Risk In patients with high CV risk, a small 12 week (N=104 for placebo comparison) study provided low-strength evidence that evolocumab 420 mg monthly resulted in higher rates of meeting LDL-C target of both <100 mg/dl and <70 mg/dl when added to statins in Japanese patients, compared to placebo. There was greater mean change in LDL-C, but insufficient evidence to draw conclusions about other outcomes. Mixed Populations: Heterozygous Familial, Statin-Intolerant, and Not At Target There was moderate-strength evidence, based on a pooled analysis of 2 open-label extension studies (OSLER 1 and 2) of patients completing 1 of 12 previous trials (patients not at target, with heterozygous familial hypercholesterolemia, or statin intolerance; N=4,465), that evolocumab 420 mg monthly or 140 mg every 2 weeks (plus standard care primarily statins) reduced LDL-C by 61% more than standard care alone at 12 weeks. This reduction was largely sustained at 48 weeks (58.4% more than usual care at week 48). These studies also provided lowstrength evidence of a greater proportion of patients meeting an LDL-C goal of <100 mg/dl or <70 mg/dl and a greater increase in HDL-C at 12 weeks than with standard therapy alone. CV events were reported as secondary or post-hoc outcomes but evidence is insufficient to draw conclusions. There was low-strength evidence that slightly more patients on evolocumab experienced any adverse event at 12 weeks compared with statins alone, without differences in serious adverse events, but insufficient evidence to draw conclusions about other adverse event outcomes. Part II. Evidence for Alirocumab Heterozygous Familial Hypercholesterolemia Compared to placebo, there was low-strength evidence that alirocumab achieved a higher LDL-C reduction in patients taking a maximum statin dose plus based on 1 fair-quality trial (N=77), with similar effects on HDL-C, but insufficient evidence to draw conclusions about harms. Evidence on alirocumab compared with placebo in patients taking a low- to moderateintensity statin was insufficient (1 fair-quality RCT, N=22). Homozygous Familial Hypercholesterolemia No evidence for alirocumab. Statin Intolerant Patients No evidence for alirocumab. Patients Not Achieving LDL-C <100 mg/dl or <70 mg/dl While on Treatment for Hypercholesterolemia Alirocumab versus Placebo in Average-Risk Patients Low-strength evidence from 2 small (N=154) fair-quality RCTs indicated that in patients stabilized on statins who had not achieved an LDL-C of <100 mg/dl, alirocumab 150 mg subcutaneously every 2 weeks for 8 to 10 weeks resulted in significantly more patients achieving study goal (LDL-C <100 mg/dl) and greater percent reductions (49% to 67% more) than statins alone. Evidence on adverse events and in subgroups, compared with statins alone, was insufficient due to small sample sizes. PCSK9 Inhibitors 5 of 9

6 Alirocumab versus Ezetimibe in High-Risk Patients Moderate-strength evidence based on a good-quality trial (ODYSSEY COMBO, N=720), that alirocumab, 75 to 150 mg given every 2 weeks, resulted in a higher proportion of patients with high CV risk reaching study goal of LDL-C <70 mg/dl at 24 weeks (RR, 1.70; 95% CI, 1.46 to 1.95) than 10 mg. Similarly, the difference in the percent change in LDL-C at 24 weeks was -29.8% (P<0.0001) and the difference in change in HDL-C was 8.1% (mean baseline LDL-C 106 mg/dl; P<0.0001). Alirocumab versus Placebo in High-Risk Patients Based on 2 trials (ODYSSEY COMBO I and ODYSSEY Long-Term; N =2656), there was highstrength evidence that alirocumab, 75 to 150 mg given every 2 weeks, resulted in a higher proportion of patients with high CV risk reaching study goal of LDL-C <70 mg/dl at 24 weeks than placebo (pooled RR, 9.65; 95% CI, 7.7 to 12.0). The difference in percent reduction in LDL-C (-45.9% to -61.9%, P<0.001; mean baseline LDL-C range 100 to 123 mg/dl) and HDL- C (7.3% to 7.6%, P<0.001) were also greater. There was moderate- and low-strength evidence of no difference in CV events between alirocumab and at 52 weeks or between alirocumab and placebo at 52 to 78 weeks (all with concomitant stain therapy). Moderate- and low-strength evidence found no differences in harms between alirocumab and or placebo (based on 3 trials), except for slightly more frequent injection site reactions with alirocumab in 1 study. Part III. Evidence for Bococizumab No completed studies. PCSK9 Inhibitors 6 of 9

7 OVERALL SUMMARY Evolocumab and alirocumab both had evidence of large LDL-C reductions, with few differences in adverse event outcomes compared with placebo or. The strongest evidence (high-strength) for evolocumab was in heterozygous familial hypercholesterolemia and those at average CV risk who had not achieved LDL-C of <100 mg/dl or <70 mg/dl with primarily statin-based treatment. For alirocumab, the strongest evidence (high-strength) was in patients at high CV risk who had not achieved LDL-C of <100 mg/dl or <70 mg/dl with primarily statin-based treatment. Important questions remain about the effects of PCSK9 inhibitors on health outcomes and effects with longer-term use. Table B. Summary of the evidence by drug and population Population Study N Patient N Evolocumab Concomitant lipid therapy PCSK9 inhibitor Dose Baseline LDL-C (mg/dl) Heterozygous Familial Hypercholesterolemia: 12 wks N=499 High-intensity statin mg every 2 wks to 420 mg every 4 wks Homozygous Familial Hypercholesterolemia: 12 wks 1 RCT N=50 wks High-intensity statin + Unable to use statins: 12 wks N=496 N/A 140 mg every 2 wks or 280 mg, 350, or 420 mg given every 4 wks (vs. 10 mg) Difference in LDL-C change Difference in % meeting goal 150 to % to -61% vs. placebo % (95% CI, to -19.2) vs. placebo 192 to % (95% CI, -34.1% to -17.9%) for 280 mg every 4 wks to -38% (95% CI, to -32.4) for 140 mg every 2 wks (vs. ) HDL-C 6.8% (P<0.01) to 9.2% (95% CI, +4.7% to +13.7%) Evolocumab reduced HDL-C by 0.1% vs. placebo (NS) Differences favored evolocumab for all doses (3.6% to 8.5%) Cardiovascular events Harms No differences No differences or lower rates of most harms, except more gastroenteritis No difference in overall AEs and SAEs. Significantly lower WAEs with evolocumab (3% vs. 12%). No neurocognitive events and too few injection site reactions to draw conclusions. to PCSK9 Inhibitors 7 of 9

8 Population Study N Patient N Concomitant lipid therapy Ezetimibe 10 mg PCSK9 inhibitor Dose wks Baseline LDL-C (mg/dl) Not achieved LDL-C <100 mg/dl or <70 mg/dl : wks Patients with varying risk of CV events: wks Statin, range of doses according to risk level wks (vs. placebo) N=1,375 Patients with high risk of CV events: 12 wks N=1,375 Statin, range of doses wks (vs. placebo or ) Mixed population with extended duration: wks 2 extension RCTs N=4,465 Usual care (primarily statins) wks Difference in LDL-C change Difference in % meeting goal -47% (95% CI, -53.7% to -40.8%) 104 Vs. placebo 52 wks: -57% (+/- 2.1 sd) LDL goal <70: 82.3% vs. 6.4% (P<0.0001) 12 wks: -53% to -70.5% vs. placebo LDL goal <70: 71.8% to 94.5% vs % 139 vs. placebo; 126 to 129 or 92 to 94 vs % (P<0.001) LDL goal <100: 96% vs. 1% (P<0.001) LDL goal <70: 82% vs. 0% (P<0.001) Vs. : LDL goal <70: 86% to 95% vs. 6% to 62% 12 wks: reduction of 61% (95% CI, 59 to 63, P<0.001) LDL goal <100: 90.2% vs. 26.0% LDL goal <70: 73.6% vs. 3.8% 48 wks: 58.4% (P<0.001) and HDL-C 52 wks: 5.4% (P<0.001) 12 wks: 4.5% (95% CI, 0.4 to 8.7) to 9.1% (95% CI, 4.4 to 13.7) to 12 wks: 8.7% vs. 1.7% (P<0.001) Cardiovascular events 48 wks: any CV event (adjudicated, but not a primary outcome): HR, 0.47 (95% CI, 0.28 to 0.78) with evolocumab Harms 52 wks: no differences (vs. placebo) to 12 wks: more overall AEs (60% vs. 42%), no difference in withdrawals, serious harms, injection site reactions to no conclusions Vs. : similar rates of overall AEs, but no conclusions on other harms outcomes to 48 wks: Overall AEs: 69.2% vs. 64.8%. No difference in serious adverse events. for other harms PCSK9 Inhibitors 8 of 9

9 Population Study N Patient N Alirocumab Concomitant lipid therapy PCSK9 inhibitor Dose Baseline LDL-C (mg/dl) Heterozygous Familial Hypercholesterolemia: 12 wks N=98 High-dose statin mg, 200 mg, or 300 mg every 4 wks or 150 mg every 2 wks (vs. placebo) to Not achieved LDL-C <100 mg/dl or <70 mg/dl : weeks Patients with average risk of CV events: 10 wks Statin, range of doses 75 to 150 mg every 2 wks (vs. or placebo) to N=124 at 150 mg dose Patients with high risk of CV events: wks Vs. 1 RCT N=720 Vs. placebo N=2,656 Statin, range of doses 75 to 150 mg every 2 wks (vs. or placebo) 106 (vs. ) 100 to 123 (vs. placebo): Difference in LDL-C change Difference in % meeting goal -8% to -57% -49% to -67% LDL <100: 100% vs. 16% to 52% (150 mg every 2 wks) vs. placebo 24 wks: Vs. : -29.8% (P<0.0001) LDL goal <70: RR 1.70 (95% CI, 1.46 to 1.95) -45.9% to -61.9% (P<0.001) LDL goal <70: RR 9.65 (95% CI, 7.7 to 12.0) HDL-C NSD except for 150 mg every 2 wks: % vs % (P=0.0496) 6% to 9% over placebo 24 wks: Vs. : 8.1% over (P<0.0001) 7.3% to 7.6% over placebo (P<0.0001) Cardiovascular events 52 wks: No difference in CV events between alirocumab and 52 and 78 wks: No differences between alirocumab and placebo Harms No differences in harms outcomes between alirocumab and or placebo, except for slightly more frequent injection site reactions with alirocumab in one study. and Strength of evidence: =High; =Moderate; =Low; =Insufficient Abbreviations: AEs, adverse events; CI, confidence interval CV, cardiovascular;, not reported; NSD, no significant difference; RCT, randomized controlled trial; SAEs, serious adverse events; sd, standard deviation; WAEs, withdrawal due to adverse events; wks, weeks PCSK9 Inhibitors 9 of 9

HMG-CoA reductase inhibitors, or statins, have been the

HMG-CoA reductase inhibitors, or statins, have been the SYSTEMATIC REVIEW A Systematic Review of PCSK9 Inhibitors Alirocumab and Marian McDonagh, PharmD; Kim Peterson, MS; Brittany Holzhammer, MPH; and Sergio Fazio, MD, PhD ABSTRACT BACKGROUND: The proprotein

More information

What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?

What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University

More information

Drug Class Review Newer Oral Anticoagulant Drugs

Drug Class Review Newer Oral Anticoagulant Drugs Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

PCSK9 Inhibitors: Promise or Pitfall?

PCSK9 Inhibitors: Promise or Pitfall? PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential

More information

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative

More information

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for

More information

Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia.

Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia. Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia. The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ) Following

More information

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016

More information

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes

More information

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate

More information

Class Update PCSK9 Inhibitors

Class Update PCSK9 Inhibitors Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors

Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill

More information

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL PCSK-9 Inhibitors for Hyperlipidemia: A Review of the Comparative Clinical Effectiveness

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL PCSK-9 Inhibitors for Hyperlipidemia: A Review of the Comparative Clinical Effectiveness CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL PCSK-9 Inhibitors for Hyperlipidemia: A Review of the Comparative Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication

More information

B. Patient has not reached the percentage reduction goal with statin therapy

B. Patient has not reached the percentage reduction goal with statin therapy Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels

More information

PCSK9 Agents Drug Class Prior Authorization Protocol

PCSK9 Agents Drug Class Prior Authorization Protocol PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical

More information

New Horizons in Dyslipidemia Management in Primary Care

New Horizons in Dyslipidemia Management in Primary Care New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin

Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative

More information

4 th and Goal To Go How Low Should We Go? :

4 th and Goal To Go How Low Should We Go? : 4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose

More information

PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia

PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia : 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University

More information

PCSK9 Inhibitors Current Status

PCSK9 Inhibitors Current Status PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Fall Conference 2015 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am

More information

Patient Lists. Epic ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information

Patient Lists. Epic ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT

More information

Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials

Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,

More information

PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials?

PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials? PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials? Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis

More information

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;

More information

Class Update PCSK9 Inhibitors

Class Update PCSK9 Inhibitors Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies

Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies Efficacy, Safety and Tolerability of 150 mg Q2W Dose of the PCSK9 mab REGN727/SAR236553: Data from Three Phase 2 Studies Michael J. Koren, 1 Evan A. Stein, 2 Eli M. Roth, 3 James M. McKenney, 4 Dan Gipe,

More information

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care

More information

PCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time?

PCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time? Original Article Thomas Knickelbine, MD, FACC, FSCCT, FSCAI From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Thomas Knickelbine, MD, FACC,

More information

PCSK9 Inhibitors Current Status

PCSK9 Inhibitors Current Status PCSK9 Inhibitors Current Status Ryan T. Whitney, MD FACC Bryan Heart Spring Conference 2016 Disclosures, Conflicts, and Nefarious Connections I own no stock in the companies mentioned in this talk. I am

More information

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,

More information

W J C. World Journal of Cardiology. PCSK9 inhibitors: A new era of lipid lowering therapy. Abstract REVIEW

W J C. World Journal of Cardiology. PCSK9 inhibitors: A new era of lipid lowering therapy. Abstract REVIEW W J C World Journal of Cardiology Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.4330/wjc.v9.i2.76 World J Cardiol 2017 February 26; 9(2): 76-91 ISSN 1949-8462 (online) REVIEW PCSK9 inhibitors:

More information

Patient List Inquiries

Patient List Inquiries ABOUT THIS GUIDE This Guide provides a high-level overview of Patient List Inquiries in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for

More information

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Patient Action Sets. Allscripts Touchworks ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION

Patient Action Sets. Allscripts Touchworks ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Action Sets in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT

More information

PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH

PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,

More information

New Approaches to Lower LDL-C

New Approaches to Lower LDL-C New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker

More information

PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy

PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for

More information

Contemporary management of Dyslipidemia

Contemporary management of Dyslipidemia Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that

More information

Patient Lists. Allscripts Professional ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION

Patient Lists. Allscripts Professional ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION ABOUT THIS GUIDE This Guide provides a high-level overview of Patient Lists in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT

More information

EVIDENCE TO DATE EVOLOCUMAB (REPATHA)

EVIDENCE TO DATE EVOLOCUMAB (REPATHA) and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does

More information

Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia

Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant

More information

Systematic review of published Phase 3 data on anti-pcsk9 monoclonal antibodies in patients with hypercholesterolaemia

Systematic review of published Phase 3 data on anti-pcsk9 monoclonal antibodies in patients with hypercholesterolaemia British Journal of Clinical Pharmacology SYSTEMATIC REVIEW Br J Clin Pharmacol (2016) 82 1412 1443 1412 Systematic review of published Phase 3 data on anti-pcsk9 monoclonal antibodies in patients with

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.

More information

Challenges in lipid management

Challenges in lipid management Challenges in lipid management Milan Gupta MD, FRCPC, FACC State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University of Toronto

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

Chapter 6. Long-Term Cardiovascular Outcomes with PCSK9 Inhibitors INTRODUCTION LIMITATIONS OF CURRENT MANAGEMENT OF DYSLIPIDAEMIA

Chapter 6. Long-Term Cardiovascular Outcomes with PCSK9 Inhibitors INTRODUCTION LIMITATIONS OF CURRENT MANAGEMENT OF DYSLIPIDAEMIA Chapter 6 Long-Term Cardiovascular Outcomes with PCSK9 Inhibitors PREMCHAND RAJENDRA KUMAR GEETESH MANIK INTRODUCTION Cardiovascular disease (CVD) is the leading cause of adult mortality and morbidity

More information

New Drugs and Technologies

New Drugs and Technologies New Drugs and Technologies Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk Nathalie Bergeron, PhD; Binh An P. Phan, MD; Yunchen

More information

PCSK9 Inhibitors: A View of Clinical Studies

PCSK9 Inhibitors: A View of Clinical Studies PCSK9 Inhibitors: A View of Clinical Studies Slide deck kindly donated for website use by Professor Raul D. Santos Lipid Clinic InCor-HCFMUSP Sao Paulo, Brazil PCSK9 Inhibitors : A View of Clinical Studies

More information

Disclosure. This study was sponsored by Pfizer, Inc. All authors are employees of Pfizer, Inc. with ownership of stock in Pfizer, Inc.

Disclosure. This study was sponsored by Pfizer, Inc. All authors are employees of Pfizer, Inc. with ownership of stock in Pfizer, Inc. Disclosure This study was sponsored by Pfizer, Inc. All authors are employees of Pfizer, Inc. with ownership of stock in Pfizer, Inc. Effects of 12 Weeks of Treatment with RN316 (PF-04950615), a Humanized

More information

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,

More information

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Evolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia

Evolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Evolocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Evolocumab (Repatha,

More information

Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17

Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy

More information

Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?

Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay

More information

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Management of Dyslipidaemias: PCSK9 Inhibition. Alberico L. Catapano Professor President EAS University of Milano Italy

Management of Dyslipidaemias: PCSK9 Inhibition. Alberico L. Catapano Professor President EAS University of Milano Italy Management of Dyslipidaemias: PCSK9 Inhibition Alberico L. Catapano Professor President EAS University of Milano Italy Conflict of interest Grants, consulting fees and/or honoraria and delivering lectures

More information

Alirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia

Alirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Alirocumab for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Alirocumab (Praluent,

More information

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394 NICE 2017. All rights reserved. Subject to

More information

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta394 NICE 2018. All rights reserved. Subject to

More information

Evan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4

Evan A. Stein 1, David Sullivan 2, Anders G. Olsson 3, Rob Scott 4, Jae B. Kim 4, Allen Xue 4, Thomas Liu 4, Scott M. Wasserman 4 Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo and Ezetimibe Controlled Study Evan A. Stein 1, David Sullivan

More information

Reports. NextGen ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information

Reports. NextGen ABOUT THIS GUIDE INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Please see accompanying full Prescribing Information ABOUT THIS GUIDE This Guide provides a high-level overview of in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates for PRALUENT (alirocumab)

More information

Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges

Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Statins and PCSK9 inhibitors for stroke prevention

Statins and PCSK9 inhibitors for stroke prevention Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l

More information

Drug Regulatory Affairs. Praluent. Summary of the Risk Management Plan (RMP) for Praluent (alirocumab)

Drug Regulatory Affairs. Praluent. Summary of the Risk Management Plan (RMP) for Praluent (alirocumab) Drug Regulatory Affairs Praluent Summary of the Risk Management Plan (RMP) for Praluent (alirocumab) Document version: 02 Document date: MAY 2018 Summary of the risk management plan (RMP) for Praluent

More information

PCSK9 Inhibitors and Modulators

PCSK9 Inhibitors and Modulators PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha

More information

Drug Class Review Newer Diabetes Medications and Combinations

Drug Class Review Newer Diabetes Medications and Combinations Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

Summary of the risk management plan (RMP) for Praluent (Alirocumab)

Summary of the risk management plan (RMP) for Praluent (Alirocumab) EMA/519153/2015 Summary of the risk management plan (RMP) for Praluent (Alirocumab) This is a summary of the risk management plan (RMP) for Praluent, which details the measures to be taken in order to

More information

Clinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

HYPERCHOLESTEROLEMIA

HYPERCHOLESTEROLEMIA UPDATES ON HYPERCHOLESTEROLEMIA WITH EMPHASIS ON PCSK9 INHIBITORS July, 2018 Chicago by Ernesto L. Chua, MD, FACC, FACP, FPCP Board Certified in Internal Medicine Board Certified in Cardiology COL, USAF,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and

More information

Beyond HDL: new therapeutic targets

Beyond HDL: new therapeutic targets Rome Cardiology Forum 2014 An ESC Update Programme in Cardiology Rome, 29-31 2014 Beyond HDL: new therapeutic targets Marcello Arca, MD Dipartimento di Medicina Interna e Specialità Mediche UOS Centro

More information

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for

More information

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date: Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017

Clinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

More information

DYSLIPIDEMIA. Michael Brändle, Stefan Bilz

DYSLIPIDEMIA. Michael Brändle, Stefan Bilz DYSLIPIDEMIA Michael Brändle, Stefan Bilz Cardiovascular risk in patients with DM Current guidelines with emphasis on patients with DM Familial Hypercholesterolemia PCSK9-inhibitors Primary Prevention

More information

Disclosures. Objectives 2/11/2017

Disclosures. Objectives 2/11/2017 Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular

More information

Registry Processor Reports

Registry Processor Reports ABOUT THIS GUIDE This Guide provides a high-level overview of Registry Processor Reports in and how they can be used to help identify clinically appropriate and approvable patients who may be candidates

More information

Deep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City

Deep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City Deep Dive into Contemporary Cholesterol Management Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO CONSENSUS IN

More information

EVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378

EVOLOCUMAB Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 Generic Brand HICL GCN Exception/Other EVOLOCUMAB REPATHA 42378 This drug requires a written request for prior authorization. All requests for Repatha (evolocumab) require review by a pharmacist prior

More information

Cardiology 2015: Status On Pharmacology News, Debates & Novelties

Cardiology 2015: Status On Pharmacology News, Debates & Novelties Cardiology 2015: Status On Pharmacology News, Debates & Novelties George D. Dangas, MD, FESC, FACC Professor of Medicine (Cardiovascular Disease) Icahn School of Medicine at Mount Sinai Zena & Michael

More information

Drug Class Review on Macrolides

Drug Class Review on Macrolides Drug Class Review on Macrolides Preliminary Scan Report 5 July 2014 Last Report: Original August 2006 The purpose of reports is to make available information regarding the comparative clinical effectiveness

More information

Best Lipid Treatments

Best Lipid Treatments Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis

More information

New Strategies for Lowering LDL - Are They Really Worth It?

New Strategies for Lowering LDL - Are They Really Worth It? New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)

More information

Repatha. Repatha (evolocumab) Description

Repatha. Repatha (evolocumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Repatha Page: 1 of 8 Last Review Date: September 15, 2016 Repatha Description Repatha (evolocumab)

More information

Non-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016

Non-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016 Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4

More information

Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making

Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO

More information

ADMINISTRATIVE POLICY AND PROCEDURE

ADMINISTRATIVE POLICY AND PROCEDURE ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce

More information

Modern Lipid Management:

Modern Lipid Management: Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)

More information

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct

More information

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

PCSK9 inhibition across a wide spectrum of patients: One size fits all? PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl

More information

Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549

Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549 2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes

More information

INTERNAL MEDICINE - PEDIATRICS

INTERNAL MEDICINE - PEDIATRICS Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 2 INTERNAL MEDICINE - PEDIATRICS UPDATES NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY A.L. Strat

More information